The value of nanocarbon contrast methylene blue based on dye-based tracer technology in sentinel lymph node biopsy for breast cancer: a systematic review and meta-analysis
PeerJ · 2025
DOI: 10.7717/peerj.19546 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PeerJ, 2025. Verfasst von Luhua Xia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Hospital Affiliated to Xinjiang Medical University, Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region Urumqi, Department of Nucle…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carbon, Contrast Media, Methylene Blue. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Xinjiang Uygur Autonomous Region Natural Science Foundation, Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region.
Abstract (Originalsprache)
Objective
The purpose of this study was to compare the diagnostic value of nanocarbon suspensions and methylene blue injections in sentinel lymph node biopsies of patients with breast cancer based on the dye method.
Methods
A systematic search of the PubMed, Embase, Cochrane Library (Central) and Web of Science (SCI Expanded) databases was performed to determine the diagnostic value of carbon nanoparticles in Chinese databases (China National Knowledge Infrastructure (CNKI), VIP, Wanfang, Chinese Biomedical Literature Database (CBM)) for identifying methylene blue in sentinel lymph node biopsies of patients with breast cancer. The QUADAS2 quality evaluation tool of Review Manager 5.4 was used to evaluate the quality of the included studies. Meta-Disc 1.4 software was used to calculate the extracted valid data and perform a heterogeneity test. STATA 14.0 software was selected to conduct a sensitivity analysis, and Deek’s publication bias test was used for the included studies.
Results
In 17 articles, the binding sensitivity of nanocarbons was 0.93 (0.90–0.95), the binding specificity was 0.98 (0.97–0.99), the binding sensitivity of methylene blue was 0.89 (0.85–0.92), and the binding specificity was 0.94 (0.92–0.95). The AUC value of the nanocarbon SROC was 0.9827 (SE = 0.0062), and the AUC value of methylene blue was 0.9495 (SE = 0.0139).
Conclusion
Nanocarbon versus methylene blue is a more satisfactory dye tracer for sentinel lymph node biopsy in breast cancer patients and should be considered a first-line diagnostic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tumor Hospital Affiliated to Xinjiang Medical University, Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region Urumqi, Department of Nuclear Medicine, Urumqi, Xinjiang, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Nuclear Medicine, Beijing, China.
- The Affiliated Cancer Hospital of Xinjiang Medical University, Department of Ultrasonography, Urumqi, Xinjiang, China.
Förderung
- The Xinjiang Uygur Autonomous Region Natural Science Foundation
- Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region
Zitieren
APA
Xia, L., Zou, Z., Chong, L., Wang, X., Dong, Z., & Zhao, Y. (2025). The value of nanocarbon contrast methylene blue based on dye-based tracer technology in sentinel lymph node biopsy for breast cancer: a systematic review and meta-analysis. PeerJ. https://doi.org/10.7717/peerj.19546
Vancouver
Xia L, Zou Z, Chong L, Wang X, Dong Z, Zhao Y. The value of nanocarbon contrast methylene blue based on dye-based tracer technology in sentinel lymph node biopsy for breast cancer: a systematic review and meta-analysis. PeerJ. 2025. doi:10.7717/peerj.19546
BibTeX
@article{Xia2025,
author = {Xia, Luhua and Zou, Zuowei and Chong, Le and Wang, Xinhua and Dong, Zhanfei and Zhao, Yanping},
title = {The value of nanocarbon contrast methylene blue based on dye-based tracer technology in sentinel lymph node biopsy for breast cancer: a systematic review and meta-analysis},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19546}
}
EUVIMED